COVID-SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults.

ABSTRACT:

Background/objectives

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causes high morbidity and mortality in older adults with chronic illnesses. Several trials are currently underway evaluating the antimalarial drug hydroxychloroquine as a potential treatment for acute infection. However, polypharmacy predisposes patients to increased risk of drug-drug interactions with hydroxychloroquine and may render many in this population ineligible to participate in trials. We aimed to quantify the degree of polypharmacy and burden of potentially inappropriate medications (PIMs) that older hospitalized adults are taking that would interact with hydroxychloroquine.

Methods

We reanalyzed data from the cohort of patients 65 years and older enrolled in the MedSafer

SUBMITTER: Ross SB 

PROVIDER: S-EPMC7280600 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature